November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Low-Dose vs. Standard-Dose Olanzapine for Chemotherapy-Induced Nausea and Vomiting in Solid Tumors
Nov 24, 2024, 14:30

Low-Dose vs. Standard-Dose Olanzapine for Chemotherapy-Induced Nausea and Vomiting in Solid Tumors

Maryam Lustberg, Director of the Center for Breast Cancer at Yale Cancer Center, shared on LinkedIn:

“Low dose olanzapine (2.5 mg) is as effective of higher dose in mitigation of toxicity in highly emetegenic chemo.

Important reminder from a previously reported study from Jyoti Bajpai. ”

Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial

Authors: Jyoti BajpaiVenkatesh KapuSushmita RathSravan KumarAnbarasan SekarPriyanka PatilAltaf SiddiquiSrikanth AnneAkash PawarSujay SrinivasPrabhat BhargavaSeema GuliaVanita NoronhaAmit JoshiKumar PrabhashShripad BanavaliRajiv SarinRajendra BadweSudeep Gupta

Low-Dose vs. Standard-Dose Olanzapine for Chemotherapy-Induced Nausea and Vomiting in Solid Tumors

More posts featuring Maryam Lustberg.

Dr. Maryam Lustberg is the Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, and Chief of Breast Medical Oncology at Yale Cancer Center. She is also an Associate Professor of Medicine (Medical Oncology).

She has been recognized for her patient-focused care with awards that include being rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of “Regional Top Doctors,” and “Exceptional Women in Medicine” for 2020.

Dr. Lustberg is a member of the ASCO Annual Meeting Education Committee, Patient and Survivor Care Education Committee, and Neuropathy Expert Guideline Panel. She is the immediate past President for the International Organization Multinational Association of Supportive Care in Cancer (MASCC). She serves as an Associate Editor for the Journal of Cancer Survivorship.